Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

被引：0
|
作者：
不详
机构：
来源：
ANNALS OF INTERNAL MEDICINE | 2014年 / 161卷 / 07期
关键词：
D O I：
10.7326/P14-9035
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：I / 22
页数：1
相关论文
共 50 条
  • [21] Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor plus protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor plus nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial
    Soulie, Cathia
    Assoumou, Lambert
    Ghosn, Jade
    Duvivier, Claudine
    Peytavin, Gilles
    Ait-Arkoub, Zaina
    Molina, Jean-Michel
    Costagliola, Dominique
    Katlama, Christine
    Calvez, Vincent
    Marcelin, Anne-Genevieve
    AIDS, 2009, 23 (12) : 1605 - 1608
  • [22] Effectiveness and Safety of Rilpivirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, in Treatment-Naive Adults Infected with HIV-1: A Meta-analysis
    Li, Sheng-li
    Xu, Peng
    Zhang, Lei
    Sun, Gui-xiang
    Lu, Zhao-jun
    HIV CLINICAL TRIALS, 2014, 15 (06): : 261 - 268
  • [23] Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis
    Li, Sheng-Li
    Xu, Peng
    Zhang, Lei
    Sun, Gui-Xiang
    Lu, Zhao-Jun
    HIV CLINICAL TRIALS, 2015, 16 (01): : 22 - 29
  • [24] The role of nonnucleoside reverse transcriptase inhibitors for the treatment of HIV-1 infection
    Wang, Qian
    Zheng, Yong-Tang
    Chinese Pharmaceutical Journal, 2002, 37 (12) : 881 - 884
  • [25] PREVENTION OF HIV-1 INFECTION IN CHIMPANZEES BY A NONNUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR
    SCHLEIF, WA
    SARDANA, VV
    BYRNES, VW
    MURTHY, KK
    EMINI, EA
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 23 - 23
  • [26] Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability
    Figueiredo, Anna
    Zelina, Shannon
    Sluis-Cremer, Nicolas
    Tachedjian, Gilda
    CURRENT HIV RESEARCH, 2008, 6 (02) : 130 - 137
  • [27] Nonnucleoside reverse transcriptase inhibitor resistance among antiretroviral-naive HIV-positive pregnant women
    Juethner, SN
    Williamson, C
    Ristig, MB
    Tebas, P
    Seyfried, W
    Aberg, JA
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (02) : 153 - 156
  • [28] HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors
    Spence, RA
    Anderson, KS
    Johnson, KA
    BIOCHEMISTRY, 1996, 35 (03) : 1054 - 1063
  • [29] Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients
    Allavena, C
    Ferré, V
    Brunet-François, C
    Delfraissy, JF
    Lafeuillade, A
    Valantin, MA
    Bentata, M
    Michelet, C
    Poizot-Martin, I
    Dailly, E
    Launay, O
    Raffi, F
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 39 (03) : 300 - 306
  • [30] Considerations in the choice of protease inhibitor-sparing regimens in initial therapy for HIV-1 infection
    Moyle, GJ
    CURRENT OPINION IN INFECTIOUS DISEASES, 2000, 13 (01) : 19 - 25
12345